For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and the formulated version represents a genuine change. These novel therapies protect the transthyretin protein, halting its destructive build-up and reducing the severity